乙型肝炎治疗市场－全球产业规模、份额、趋势、机会、预测：按类型、治疗方法、分销管道、地区和竞争格局划分，2021-2031年

全球乙肝治疗市场预计将从 2025 年的 51.1 亿美元成长到 2031 年的 65.2 亿美元，复合年增长率为 4.14%。

该市场涵盖免疫调节剂和抗病毒药物的分销，这些药物旨在抑制病毒复製并减轻肝损伤。推动该产业发展的关键因素包括全球慢性感染疾病的不断增加，以及各国政府加强筛检和疫苗接种力度，凸显了开发有效治疗方案的迫切性。根据世界卫生组织（世卫组织）估计，到2024年，全球将有约2.54亿人感染慢性B型肝炎。

另一方面，市场扩张的一大障碍是漏诊率居高不下，尤其是在开发中国家。终身治疗费用高昂，加上医疗基础设施不足，导致许多感染者无法获得必要的治疗。该疾病的高发病率与低确诊病例数之间的巨大差距限制了具有商业性可行性的市场规模，并对旨在进行全球扩张的製药公司构成了重大挑战。

市场驱动因素

对功能性治癒疗法的研发投入不断增加，正从根本上改变全球B型肝炎治疗市场。研究重点正从终身抑制病毒毒力模式转向恢復免疫调节功能的有限疗程治疗。製药创新者正积极探索新的治疗方法，例如小干扰RNA和衣壳组装调节剂，这些疗法会攻击病毒生命週期的不同阶段，以实现持续的血清学清除。这些努力已取得令人鼓舞的临床成果。例如，2025年5月，Vir Biotechnology公司公布了初步的II期临床试验数据，显示其在研联合治疗在特定患者亚群中实现了15%的功能性治癒率。这表明，治疗策略正朝着克服现有核苷类似物局限性的根治性治疗方法转变。

同时，政府主导的筛检和免疫接种倡议的扩大正在改善患者的检出率和治疗可及性，尤其是在感染率高的地区。在加强预防资源取得的国际伙伴关係的支持下，各国卫生策略正日益采纳消除病毒的目标。根据乙肝基金会2024年度报告，全球疫苗免疫联盟（Gavi Alliance）于2024年6月在32个非洲国家启动了B肝新生儿疫苗接种宣传活动。这些公共卫生措施正在增加确诊患者的数量，并增强抗病毒药物生产商的商业性前景。吉利德科学公司在2025年2月宣布，其2024年全年产品销售额（不包括Veklur）成长了8%，主要得益于其肝病治疗产品组合的成长，这一趋势也印证了上述趋势。

市场挑战

限制B型肝炎治疗市场经济发展的主要因素是严重的漏诊率。儘管全球盛行率显示抗病毒药物的潜在使用者群体庞大，但由于绝大多数人并不了解自身感染状况，商业性可获得的市场规模要小规模。这种普遍存在的认知不足导致现有病例数与积极寻求医疗服务的患者人数之间存在巨大差距，从而有效地限制了药品生产商的商机。

诊断缺口直接限制了处方量，阻碍了现有药物的广泛应用。儘管库存充足，但只要大多数感染者仍未纳入医疗体系，製药公司的成长就面临瓶颈。世界卫生组织（世卫组织）预测，到2024年，只有13%的慢性B型肝炎患者能够得到诊断。这一数字凸显出，目前製药动态仅服务部分患者群体，导致市场潜在需求远超实际销售。

市场趋势

透过活化宿主减弱的T细胞反应，治疗性疫苗的临床试验正成为实现持续病毒控制的关键策略重点。与主要抑制病毒复製的标准抗病毒药物不同，这些实验性疫苗旨在刺激特异性免疫，从而使患者能够完成终身治疗。这一策略正在稳步推进。在2024年11月发布的关于2b期临床试验结果的新闻稿中，Valinsus Biotherapeutics公司报告称，接受候选疫苗VTP-300治疗的8名受试者实现了乙肝表面抗原清除，其中2名受试者达到了功能性治癒的标准，这凸显了疫苗克服免疫耐受的潜力。

同时，市场对具有免疫调节作用的候选药物，特别是旨在快速降低病毒抗原量的单株抗体，越来越感兴趣。研发人员正致力于开发能够清除循环乙型肝炎表面抗原（HBsAg）并消除关键免疫抑制机制以促进康復的药物。这一趋势在近期的临床结果中得到了印证。 2024年11月，Blue Jay Therapeutics公司宣布，所有每週接受300毫克单株抗体BJT-778治疗的受试者，均在第44週达到病毒学反应。这项进展表明，整个产业正朝着免疫疗法的方向发展，免疫疗法与直接抗病毒药物联合使用，可提高功能性治癒率。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球B型肝炎治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（急性、慢性）
  • 治疗方法（免疫调节药物、抗病毒药物、疫苗、手术）
  • 通路（医院药局、零售药局、网路药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美B型肝炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲乙型肝炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区乙型肝炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲B型肝炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲B型肝炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球B型肝炎治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Accord Healthcare Inc.
• Apotex Corp.
• Arbutus Biopharma Corp
• Arrowhead Pharma Inc
• Aurobindo Pharma Limited
• Lupin Pharmaceuticals Inc.
• Merck & Co. Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hepatitis B Treatment Market is projected to expand from USD 5.11 Billion in 2025 to USD 6.52 Billion by 2031, registering a CAGR of 4.14%. This market encompasses the distribution of immune modulators and antiviral medications designed to suppress viral replication and mitigate liver injury. Key factors driving this industry include the growing worldwide incidence of chronic infections alongside enhanced governmental efforts regarding screening and vaccination, highlighting the urgent requirement for potent therapeutic solutions. As reported by the World Health Organization, an estimated 254 million individuals globally were living with chronic hepatitis B infection in 2024.

Conversely, a significant obstacle retarding market expansion is the high frequency of underdiagnosis, especially within developing nations. The expensive nature of lifelong therapy combined with insufficient healthcare infrastructure prevents a large segment of the infected population from receiving essential care. This gap between the high prevalence of the disease and the low volume of diagnosed patients constrains the commercially viable market, establishing a substantial hurdle for pharmaceutical firms seeking to broaden their global presence.

Market Driver

Increased research and development funding for functional cure therapies is fundamentally transforming the Global Hepatitis B Treatment Market, moving from lifelong viral suppression models to finite treatment courses that reinstate immune regulation. Pharmaceutical innovators are actively exploring new modalities, such as small interfering RNAs and capsid assembly modulators, which attack distinct phases of the viral lifecycle to realize sustained seroclearance. These efforts are producing encouraging clinical results; for instance, Vir Biotechnology reported in May 2025 that preliminary phase 2 study data showed its investigational combination therapy attained a 15% functional cure rate in a specific patient subgroup, signaling a strategic shift toward curative treatments that overcome the limitations of existing nucleoside analogues.

At the same time, the broadening of government-led screening and immunization initiatives is improving patient detection and access to care, especially in areas with high infection rates. National health strategies are increasingly adopting viral elimination targets, backed by international partnerships that enhance access to preventative resources. According to the Hepatitis B Foundation's 2024 Annual Report, the Gavi alliance initiated a campaign in June 2024 to roll out the hepatitis B birth dose vaccine in 32 African nations. These public health efforts are enlarging the diagnosed patient base, thereby bolstering the commercial prospects for antiviral producers, a trend reflected by Gilead Sciences in February 2025, when the company announced an 8% rise in full-year 2024 product sales (excluding Veklury) driven largely by its liver disease portfolio.

Market Challenge

The major limitation hindering the full economic development of the hepatitis B treatment market is the substantial rate of underdiagnosis. While the global prevalence indicates a vast pool of potential antiviral users, the commercially accessible market is much smaller because the majority of individuals are unaware of their infection status. This widespread lack of awareness causes a significant disconnect between the number of existing cases and those actively seeking medical treatment, effectively curtailing revenue opportunities for manufacturers of therapeutic agents.

This gap in diagnosis directly limits prescription volumes and hampers the adoption of existing medications. Despite having sufficient inventory, pharmaceutical companies encounter a growth ceiling as long as most infected individuals remain outside the healthcare network. According to the World Health Organization, only 13 percent of people living with chronic hepatitis B had been diagnosed by 2024. This figure underscores that the industry currently serves only a fraction of the total patient population, creating a market dynamic where potential demand significantly outstrips actual sales.

Market Trends

The clinical testing of therapeutic vaccines is becoming a key strategic priority aimed at achieving sustained viral control by revitalizing the host's depleted T-cell response. In contrast to standard antivirals that mainly suppress replication, these experimental vaccines seek to stimulate specific immunity, potentially allowing patients to end lifelong treatment. This strategy is demonstrating real progress; according to a November 2024 press release regarding ongoing Phase 2b trial results, Barinthus Biotherapeutics reported that eight subjects treated with candidate VTP-300 achieved HBsAg loss at some point, with two qualifying as functional cures, highlighting the promise of vaccination in overcoming immune tolerance.

Concurrently, there is a notable market emphasis on immunomodulatory candidates, specifically monoclonal antibodies engineered to swiftly lower viral antigen loads. Developers are focusing on agents capable of depleting circulating hepatitis B surface antigen (HBsAg), thereby eliminating a key immune suppression mechanism to aid recovery. This trend is illustrated by recent clinical achievements; Bluejay Therapeutics announced in November 2024 that 100% of participants receiving a 300 mg weekly dose of their monoclonal antibody BJT-778 achieved a virologic response by Week 44. Such progress signifies a wider industry movement toward immunotherapies that work alongside direct-acting antivirals to improve functional cure rates.

Key Market Players

• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Accord Healthcare Inc.
• Apotex Corp.
• Arbutus Biopharma Corp
• Arrowhead Pharma Inc
• Aurobindo Pharma Limited
• Lupin Pharmaceuticals Inc.
• Merck & Co. Inc.

Report Scope

In this report, the Global Hepatitis B Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis B Treatment Market, By Type

• Acute
• Chronic

Hepatitis B Treatment Market, By Treatment

• Immune Modulator Drugs
• Antiviral Drugs
• Vaccines
• Surgery

Hepatitis B Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hepatitis B Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis B Treatment Market.

Available Customizations:

Global Hepatitis B Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatitis B Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Acute, Chronic)
  • 5.2.2. By Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccines, Surgery)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Hepatitis B Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hepatitis B Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Hepatitis B Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Hepatitis B Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Hepatitis B Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hepatitis B Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Hepatitis B Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Hepatitis B Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Hepatitis B Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Hepatitis B Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Hepatitis B Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hepatitis B Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Hepatitis B Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Hepatitis B Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Hepatitis B Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Hepatitis B Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Hepatitis B Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hepatitis B Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Hepatitis B Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Hepatitis B Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. South America Hepatitis B Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hepatitis B Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Hepatitis B Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Hepatitis B Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hepatitis B Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Gilead Sciences, Inc.
• 15.3. GlaxoSmithKline PLC
• 15.4. Accord Healthcare Inc.
• 15.5. Apotex Corp.
• 15.6. Arbutus Biopharma Corp
• 15.7. Arrowhead Pharma Inc
• 15.8. Aurobindo Pharma Limited
• 15.9. Lupin Pharmaceuticals Inc.
• 15.10. Merck & Co. Inc.

16. Strategic Recommendations

17. About Us & Disclaimer